457 related articles for article (PubMed ID: 8680053)
21. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.
Behrend M
BioDrugs; 2001; 15(1):37-53. PubMed ID: 11437674
[TBL] [Abstract][Full Text] [Related]
22. Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment.
Hutchinson P; Jose M; Atkins RC; Holdsworth SR
Transpl Immunol; 2004; 13(1):55-61. PubMed ID: 15203129
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacology of mycophenolate mofetil: recent data and clinical consequences].
Thervet E; Anglicheau D; Legendre C
Nephrologie; 2001; 22(7):331-7. PubMed ID: 11817210
[TBL] [Abstract][Full Text] [Related]
24. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen.
Ohata K; Espinoza JL; Lu X; Kondo Y; Nakao S
Biol Blood Marrow Transplant; 2011 Feb; 17(2):205-13. PubMed ID: 20736080
[TBL] [Abstract][Full Text] [Related]
25. Rescue therapy with mycophenolate mofetil. Mycophenolate Mofetil Renal Refractory Rejection Study Group.
Tomlanovich SJ
Transplant Proc; 1996 Dec; 28(6 Suppl 1):34-6. PubMed ID: 8962412
[TBL] [Abstract][Full Text] [Related]
26. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
[TBL] [Abstract][Full Text] [Related]
27. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.
Vannozzi F; Filipponi F; Di Paolo A; Danesi R; Urbani L; Bocci G; Catalano G; De Simone P; Mosca F; Del Tacca M
Transplant Proc; 2004 Nov; 36(9):2787-90. PubMed ID: 15621150
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive activity of mycophenolate mofetil.
Eugui EM; Allison AC
Ann N Y Acad Sci; 1993 Jun; 685():309-29. PubMed ID: 8363235
[No Abstract] [Full Text] [Related]
29. Mycophenolate mofetil for the induction and maintenance treatment of lupus nephritis.
González-Rivera TC; McCune J
Immunotherapy; 2011 Dec; 3(12):1431-40. PubMed ID: 22091679
[TBL] [Abstract][Full Text] [Related]
30. Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients.
Neuberger M; Sommerer C; Böhnisch S; Metzendorf N; Mehrabi A; Stremmel W; Gotthardt D; Zeier M; Weiss KH; Rupp C
Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):543-550. PubMed ID: 31924555
[TBL] [Abstract][Full Text] [Related]
31. Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes.
Jagodzinski P; Lizakowski S; Smolenski RT; Slominska EM; Goldsmith D; Simmonds HA; Rutkowski B
Clin Sci (Lond); 2004 Jul; 107(1):69-74. PubMed ID: 14723603
[TBL] [Abstract][Full Text] [Related]
32. Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.
Quéméneur L; Flacher M; Gerland LM; Ffrench M; Revillard JP; Bonnefoy-Berard N
J Immunol; 2002 Sep; 169(5):2747-55. PubMed ID: 12193749
[TBL] [Abstract][Full Text] [Related]
33. Mycophenolate mofetil.
Sollinger HW
Kidney Int Suppl; 1995 Dec; 52():S14-7. PubMed ID: 8587275
[TBL] [Abstract][Full Text] [Related]
34. Apoptosis of superantigen-activated T cells induced by mycophenolate mofetil treatment.
Izeradjene K; Revillard JP
Transplantation; 2001 Jan; 71(1):118-25. PubMed ID: 11211176
[TBL] [Abstract][Full Text] [Related]
35. From mechanisms to long-term benefits.
Mamelok R
Transplantation; 2005 Feb; 79(3 Suppl):S43-4. PubMed ID: 15699749
[TBL] [Abstract][Full Text] [Related]
36. Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells.
Morath C; Zeier M
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):465-9. PubMed ID: 14703952
[TBL] [Abstract][Full Text] [Related]
37. Mycophenolate mofetil in pediatric renal transplantation.
Weber LT; Höcker B; Mehls O; Tönshoff B
Minerva Urol Nefrol; 2003 Mar; 55(1):91-9. PubMed ID: 12773970
[TBL] [Abstract][Full Text] [Related]
38. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation.
Allison AC; Eugui EM
Transplant Proc; 1994 Dec; 26(6):3205-10. PubMed ID: 7998117
[No Abstract] [Full Text] [Related]
39. Effects of mycophenolic acid mofetil on acute rejection of kidney allografts in rats.
Heemann U; Azuma H; Schmid C; Philipp T; Tilney N
Clin Nephrol; 1996 May; 45(5):355-7. PubMed ID: 8738672
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients.
Langman LJ; LeGatt DF; Halloran PF; Yatscoff RW
Transplantation; 1996 Sep; 62(5):666-72. PubMed ID: 8830834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
